Factors that modify risk related to APOE variants have been examined primarily in unrelated patients and controls, but seldom in family-based studies. Stroke, vascular risk factors, estrogen replacement therapy (ERT), head injury (HI), and smoking have been reported to influence risk of sporadic but not familial Alzheimer disease (AD). Objectives: To examine the potential relationship between these risk factors and APOE, the authors used a family study design in a population in which the APOE-ε4 variant is strongly associated with risk of AD. Methods: Latino families primarily from the Caribbean Islands in which two or more living relatives had dementia were identified in the New York City metropolitan area, the Dominican Republic, and Puerto Rico. A total of 1,498 participants from 350 families underwent a clinical interview, medical and neurologic examinations, neuropsychological testing, and APOE genotyping. Diagnosis was made by consensus using research criteria for AD. Results: APOE-ε4 was associated with a nearly twofold increased risk of AD. A history of stroke was also associated with a fourfold increased risk. A statistical interaction between APOE-ε4 and stroke was observed. Women with an APOE-ε4 who took ERT did not have an increased risk of AD, but in women with a history of stroke ERT was a deleterious effect modifier. Conclusions: APOE-ε4 and stroke independently increase risk of familial Alzheimer disease (AD) among Latinos, and may interact to further increase AD risk. Among women, the risk of AD associated with APOE-ε4 may be attenuated by a history of ERT. NEUROLOGY 2006;66:35-40 APOE represents the most robust genetic risk factor for late-onset Alzheimer disease (AD).
Family-based studies facilitate the investigation of the effects of putative modifiers on genetic variants and disease risk because they are less susceptible to population stratification than case-control studies. They have been relatively underutilized in the neurology literature, especially with regard to the study of non-genetic risk factors because of the difficulty in identifying large groups of families with a specific disease and ascertaining the appropriate information. [16] [17] [18] For this report, we used a family-based study to simultaneously examine the modifying effects of several risk factors on the APOE-associated risk of AD.
Methods. Setting and subjects. Details of the source population and recruitment, ascertainment of probands and their family members, and diagnostic methods have been reported in detail previously. 15 A total of 1,498 participants from 350 families were recruited from The AD Research Center/Memory Disorders Center, physicians' private offices, general medical services at Columbia University Medical Center, an ongoing population-based community study of dementia in the Washington Heights-Inwood community of northern Manhattan, NY, and from clinics in the Dominican Republic and Puerto Rico.
Data collection. Patients with AD and both affected and unaffected family members underwent standardized clinical interviews and medical, neurologic, and neuropsychological examinations. Information regarding risk factors was obtained directly from the individual if cognitive function was intact (as determined by the interviewer) using a structured questionnaire 19 ; for patients with more severe cognitive dysfunction, the information was obtained from an informant, usually a relative or caregiver. The risk factor questionnaire has been previously shown to be highly reliable. 19 History of stroke, hypertension (HTN), diabetes mellitus (DM), and myocardial infarction (MI) were defined as ever being diagnosed or treated for these conditions. ERT was defined as ever having taken female hormone pills after menopause, head injury (HI) was defined as ever having had a injury that resulted in loss of consciousness or amnesia, and smoking was defined as having ever smoked at least one cigarette per day for at least 1 year. We corroborated information obtained on clinical interview with available family members or the participant's medical record.
Diagnostic evaluations. Patients diagnosed with AD were required to meet National Institute of Neurologic and Communicative Disorders and Stroke and the AD and Related Disorders Association (NINDCS-ADRDA) research criteria for probable or possible AD. 20 Brain imaging was available and reviewed 201 affected individuals. We also offered imaging as medically necessary to support the NINDCS-ADRDA criteria. Most patients had routine laboratory studies. Patients in the Dominican Republic and Puerto Rico were offered the same diagnostic examinations. Neuropsychological examinations were given in Spanish [21] [22] [23] to all participating family members and probands regardless of affection status. All available clinical data were reviewed at a consensus conference of neurologists and neuropsychologists, the methods and development of which have been previously outlined in detail. 21, 22 Blood samples were collected from all patients with AD, their living siblings, and other family members. A modification 24 Logistic regression was used for preliminary multivariate analyses using statistical software (SPSS version 11.0, SPSS Inc., Chicago, IL). Multivariate analyses were also completed using generalized estimating equations (GEE) in which each family was treated as a cluster, and ORs were derived from these analyses. Models were completed using the GENMOD procedure in SAS (SAS Institute, Cary, NC). 26 To investigate the influence of environmental risk factors on AD GEE logistic regression analyses for each risk factor (stroke, HTN, DM, MI, ERT, HI, and smoking) were performed with AD as the outcome variable. When we conducted analyses for stroke, HTN, DM, MI, HI, and smoking, we included APOE-ε4 status, age, sex, and years of education as covariates. Analyses for ERT were limited to women, and we adjusted for ε4 status, age, and years of education. Each model was inspected to determine the effects of the non-genetic factors adjusting for APOE-ε4. We also calculated the percent change in beta estimates for APOE-ε4 in each model to determine whether the non-genetic factor modified the point estimate for APOE-ε4. A priori we considered a 10% change in beta estimate from the estimate for APOE-ε4 in the reduced model as the criterion for effect modification. For stroke and ERT, interaction terms were formed by multiplying the individual variables (stroke and APOE-ε4 in one analysis, ERT and APOE-ε4 in a second). In GEE logistic regression models we included the covariates age, education, sex, and APOE-ε4. In a second set of analyses dummy variables were created according to ERT and APOE-ε4 and included in the GEE logistic regression model with age, education, and ERT use as covariates. Patients lacking both a history of ERT and APOE-ε4 were used as the reference group. A similar analysis was used to investigate the potential interaction between stroke and ε4 status. Finally, a GEE logistic regression analysis was performed that included stroke, ERT, and APOE-ε4 with age and education as covariates.
Results. Demographics and clinical data. There were 385 families with an average of four participating family members per family. A total of 39 families (7.5%) had four or more affected individuals. A total of 778 of the 1,498 participants (51.9%) were diagnosed with AD (table 1) . Of 85 patients who had a history of stroke, 67 (78.8%) were diagnosed with AD. Among 96 women who used ERT, 19 (19.8%) had AD. Family characteristics and demographic, risk factor, and APOE genotype data are presented in table 1. Patients with AD were older, had fewer years of education, were more likely to have a history of stroke, and were less likely to have a history of ERT than unaffected family members. History of HTN, DM, MI, HI, and smoking did not significantly differ between groups with and without AD. Patients with AD were more likely to have one or more APOE-ε4 alleles than their unaffected family members.
Risk of AD associated with APOE-4. Presence of one or more ε4 alleles was associated with increased risk of AD in unadjusted analysis (OR 1.5, 95% CI 1.2 to 1.9). Adjusting for age, sex, and education increased the point estimate for the association (overall OR ϭ 1.8, 1.4 to 2.4; homozygosity OR ϭ 2.3, 1.5 to 3.5; heterozygosity OR ϭ 1.7, 1.3 to 2.3).
Individual risk factors, APOE, and AD risk. The effects of non-genetic risk factors and APOE on risk of AD are summarized in table 2. Stroke was associated with a threefold increase in risk of AD (crude: OR ϭ 3.9; 2.3 to 6.9, adjusted: OR ϭ 3.3; 1.8 to 6.1), while ERT was associated with a decreased risk of AD (crude: OR ϭ 0.2; 0.1 to 0.3, adjusted: OR ϭ 0.3; 0.2 to 0.6). Among cardiovascular risk factors, DM, MI, HI, HTN, and smoking were not associated with AD. Although a history of HTN was not associated with AD in crude analysis, in adjusted analysis an apparent decreased risk was observed (crude: OR ϭ 1.2; 1.0 to 1.5, adjusted: OR ϭ 0.7; 0.6 to 0.9). As those with HTN were older (p Ͻ 0.001) and less educated (p Ͻ 0.001) than those without HTN among the non-diseased, and both older age and lower education were associated with AD (shown above), this effect appeared to be the result of joint (positive) confounding by age and education on an underlying negative HTN-AD association. In regression analyses, adjustment for HTN, DM, MI, HI, and smoking did not modify the ε4-associated risk of AD.
Stroke, APOE, and AD risk. Of 44 patients with both a history of stroke and at least one APOE-ε4 allele, 39 (88.6%) were diagnosed with AD, compared to 28 of 41 patients with stroke and no APOE-ε4 allele (68.3%). Although regression analysis failed to show multiplicative interaction the effects did appear to be strongly additive. As shown in table 3, compared to those with no APOE-ε4 allele and no history of stroke, those with one or more APOE-ε4 alleles and a history of stroke had an 11-fold increased risk of AD.
Estrogen use, APOE, and AD risk. Adjusting for ERT use resulted in greater ε4-associated AD risk (change in beta estimate ϭ 19.4%; OR 2.1, 95% CI 1.4 to 3.0), suggesting that ERT may act as a protective effect modifier. ERT was not associated with ε4 status among the unaffected family members (p ϭ 0.555), and thus did not meet criteria for a potential confounder of the ε4 -AD association. Compared to those with no APOE-ε4 allele and no history of ERT, women without APOE-ε4 who took ERT had an 80% AD risk reduction (OR ϭ 0.2; 0.1 to 0.5). Remarkably, women with APOE-ε4 but no history of ERT had a twofold increased risk of AD (OR ϭ 1.9; 1.3 to 2.9), while those with both APOE-ε4 and a history of ERT had no increased risk (OR ϭ 0.8; 0.3 to 1.8, tables 4 and 5).
Stroke, estrogen use, APOE, and AD risk. Among women, inclusion of ERT in a regression model including stroke, APOE-ε4, age, and education revealed evidence of mild positive effect modification of ERT on the strokeassociated AD risk (change in beta estimate ϭ Ϫ13.7%). Controlling for ERT, the stroke-associated risk of AD remained elevated (OR ϭ 2.8; 1.4 to 5.7), less than in the model without ERT above. ERT remained protective in this analysis (OR ϭ 0.3; 0.2 to 0.6), and was not modified by the presence of stroke in the model (change in beta estimate Ͻ1%). Overall, APOE-ε4 (OR ϭ 2.0; 1.3 to 3.0), stroke, and ERT appeared to be independent risk factors among women for AD, with partial positive effect modification of ERT on stroke-associated AD risk.
Discussion. APOE is strongly associated with late-onset familial AD in Latinos from the Caribbean. 15 The focus of this study was to investigate the modifying effects of several risk factors on APOE-ε4 associated risk of AD. We found that the risk of AD associated with APOE-ε4 and stroke was strongly additive even after restricting the analysis to patients with probable AD. A history of ERT was associated with a protective effect in the absence of an APOE-ε4 allele, and appeared to attenuate the APOE-ε4-associated risk among women.
Systemic vascular disease has been reported to be associated with an increased rate of cognitive decline 27, 28 and increased risk of AD 29 in the setting of APOE-ε4. One longitudinal study has shown an in- (5) 361 (95) Unaffected, n (%) 77 (21) 289 (79) Differences are statistically significant, p Ͻ 0.001.
ERT ϭ estrogen replacement therapy; AD ϭ Alzheimer disease.
creased rate of cognitive decline associated with DM among persons with APOE-ε4. 27 While no association was observed between DM, MI, and APOE-ε4 here, stroke was associated with a threefold increase in AD risk. The relationships between vascular risk factors, stroke, APOE, and AD are at present unclear. In one longitudinal study, 13 a history of stroke was associated with an increased risk of AD, and the stroke-associated risk was strengthened by the presence of HTN, DM, and heart disease. Although APOE genotype was not considered, data from the Cache County Study 30 support the findings of increased stroke-associated risk of AD in the presence of vascular risk factors. The presence of APOE-ε4 has been shown to be a risk factor for dementia with stroke in two population-based case-control studies. 31, 32 Our results suggest that a history of stroke in the presence of APOE-ε4 increases risk of AD substantially. One potential explanation is that stroke in persons with APOE-ε4 may promote the pathologic process of AD. Alternatively, the presence of APOE-ε4 may modify the brain's response to vascular injury, 33, 34 increasing the degree of cognitive dysfunction resultant from a given stroke in a patient with incipient AD. Although little is known about the possible role of APOE in the molecular events following stroke in the setting of AD, the relationship between vascular injury, APOE, and AD on a molecular level is deserving of further study.
ERT may have a protective effect on the risk of AD associated with APOE-ε4. There are conflicting results in the literature with regard to ERT effects on AD risk. Estrogen use in postmenopausal women has been associated with AD risk reductions of about 50% in several case-control [35] [36] [37] [38] and cohort [5] [6] [7] studies. However, in the Women's Health Initiative Memory Study [39] [40] [41] [42] both unopposed conjugated equine estrogens alone or with progesterone were not protective, and were accompanied by an increased risk of dementia and declining cognitive test performance. Additionally, randomized controlled trials of conjugated equine estrogens in women already diagnosed with AD [43] [44] [45] have failed to show benefit in terms of cognitive performance, global assessment of change, activities of daily living, mood, or regional brain perfusion. Notably, the majority of these studies 6, [35] [36] [37] [38] [39] [40] [41] [42] [43] 45 have not controlled for APOE genotype. In the present study, of the 65 women who were APOE-ε4 homozygous, only 7 had taken ERT. Although we cannot address the effects of ERT on AD risk associated with ε4 homozygosity, our results suggest that a history of ERT may attenuate the ε4-associated risk of late-onset familial AD among women in this population.
One possible alternative explanation for an apparent protective effect of ERT on the development of AD is that hormone users tend to be healthier and lead more healthy lifestyles, 46 a limitation of several previous observational studies. 47 Although subjects in our sample who took ERT were younger (p Ͻ 0.001) and better educated (p Ͻ 0.001), there was no difference from those who did not take ERT with regard to history of several systemic diseases, stroke, seizure, alcohol or tobacco use, or APOE status (table 6). We adjusted for age and education in our multivariate analyses involving ERT.
We did not demonstrate an association between HI and APOE-ε4 in this study, consistent with other investigations. [48] [49] [50] Smoking has been reported to increase risk of AD in patients lacking an ε4 allele in two population-based cohort studies, 11, 12 but this association was not observed in the current study. Although the sample size in our study was large enough, a limitation of family studies is overmatching due to similar environmental exposures between affected and unaffected relatives. 16, 17 Methodologic limitations of many of the previously published observational studies of dementia include AD ϭ Alzheimer disease; ERT ϭ estrogen replacement therapy. use of proxy respondents to ascertain history of risk factor exposure and lack of rigor in classification of patients based on dementia status. Although our study is susceptible to information bias, our data were obtained in a structured interview with each individual participant, using another informant as the primary source only if the participant was unable to provide accurate information. We attempted to corroborate information obtained on clinical interview with available family members and medical record data, and used standardized risk factor and family history questionnaires previously shown to be reliable and valid in this setting. 19, 23 Each participant underwent a standardized neurologic and neuropsychological evaluation leading to a consensus diagnosis based on research diagnostic criteria.
The concept of gene-environment interaction is controversial primarily because it is unclear whether the term implies a true biologic interaction or a statistical one. 51 The results of the current study imply that a history of stroke substantially increases the risk of AD among individuals with an APOE-ε4 allele, while ERT use could lessen the APOE-ε4 associated risk of AD. We have not established biologic explanations for either interaction or modification, but instead have observed effects on the strength of the associations based on statistical analysis. Clearly if these analyses are replicated by others, biologic studies should follow.
